SDF-1 Delivery for Ischemic Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic cardiomyopathy fail to effectively improve myocardial function and vasculogenesis in ischemic heart tissue, leading to persistent damage and dysfunction.
Innovation Solution
Administration of SDF-1 plasmid directly to weakened, ischemic, or peri-infarct regions of the myocardial tissue using catheterization, expressing SDF-1 to enhance vasculogenesis and improve cardiac function by optimizing the amount, concentration, and delivery of SDF-1 to specific cardiac regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for ischemic cardiomyopathy, then the treatment approach is simple and widely available, but the myocardial function and vasculogenesis are not effectively improved
Solution Approach 1:
The treatment targets specific segmented regions of the heart (ischemic myocardium, peri-infarct border zone, and infarct core) rather than the entire organ, allowing localized delivery of SDF-1 to areas most in need of vasculogenesis and functional improvement while avoiding unnecessary treatment of healthy tissue
Solution Approach 2:
SDF-1 acts as an intermediary substance that mediates the therapeutic effect by recruiting bone marrow-derived progenitor cells to the ischemic myocardium, where it then promotes vasculogenesis and improves cardiac function indirectly through cellular recruitment rather than direct mechanical or chemical action on the tissue
2Reliability
If SDF-1 is administered to improve vasculogenesis and cardiac function, then myocardial function and vasculogenesis are significantly improved, but the treatment requires localized delivery to specific cardiac regions
Solution Approach 1:
The treatment applies local quality by delivering SDF-1 specifically to the ischemic myocardium and peri-infarct border zone rather than systemically throughout the body, concentrating the therapeutic effect where it is most needed while minimizing exposure to non-target tissues
Solution Approach 2:
SDF-1 serves as a mediator that recruits bone marrow-derived progenitor cells to the target site, where these cells then carry out the actual therapeutic function of promoting vasculogenesis and improving cardiac function, allowing SDF-1 to work indirectly through cellular recruitment
3Manufacturing precision
If SDF-1 delivery is optimized for specific cardiac regions, then vasculogenesis and cardiac function are significantly improved, but the treatment requires precise localization to ischemic tissue
Solution Approach 1:
The treatment achieves local quality by concentrating SDF-1 delivery specifically in the ischemic myocardium and peri-infarct border zone, creating a high local concentration of the therapeutic agent precisely where pathological changes have occurred and vasculogenesis is most needed
Solution Approach 2:
The heart is segmented into distinct functional zones (ischemic myocardium, peri-infarct border zone, and infarct core), and the treatment is applied selectively to the ischemic myocardium and border zone regions that show potential for recovery through vasculogenesis, while avoiding the irreversibly damaged core
Data Source
AI summary
A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.